These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 8682640)

  • 1. Lipid lowering and coronary risk.
    Gotto AM
    Isr J Med Sci; 1996 Jun; 32(6):355-9. PubMed ID: 8682640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive lipid-lowering therapy: a clinical imperative.
    Pedersen TR
    Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Why the cardiologists should be interested in lipids?].
    López-Sendón JL; Rubio R; López de Sá E; Delcán JL
    Rev Esp Cardiol; 1995; 48 Suppl 2():23-32. PubMed ID: 7569272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regression of coronary atherosclerosis: possible--and clinically relevant?].
    Niederhauser HU
    Schweiz Rundsch Med Prax; 1991 Sep; 80(39):1019-23. PubMed ID: 1925225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical investigations of the arrest and reversal of coronary artery disease.
    Farmer JA; Gotto AM
    Coron Artery Dis; 1995 Jun; 6(6):457-65. PubMed ID: 7551266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-altering therapies and the progression of atherosclerotic disease.
    Wierzbicki AS
    Cardiovasc Intervent Radiol; 2007; 30(2):155-60. PubMed ID: 17206389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of lipid lowering measures on coronary perfusion].
    Steinmetz A; Maisch B; Noll B
    Z Kardiol; 1997; 86 Suppl 1():43-55. PubMed ID: 9173721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Med; 2005 Dec; 118 Suppl 12A():22-7. PubMed ID: 16356804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is regression of atherosclerosis possible?].
    Thomas D; Richard JL; Emmerich J; Bruckert E; Delahaye F
    Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():47-57. PubMed ID: 1296545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reduction of coronary events: what are the possible mechanisms?].
    Badimón L; Pueyo Palazón C; Varela Villén O; Viñals Izquierdo M
    Rev Esp Cardiol; 1995; 48 Suppl 2():18-22. PubMed ID: 7569271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.